NORTH CHICAGO, Ill., Jan. 31, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced financial results for the fourth quarter and full year ended Dec. 31, 2013.

NORTH CHICAGO, Ill., Jan. 15, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the initiation of a Phase 3 clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888) when added to carboplatin, a chemotherapy, in women with early-stage, triple-negative breast cancer.  The three-arm trial will compare the addition of veliparib plus carboplatin or placebo plus carboplatin to standard neoadjuvant chemotherapy. 

NORTH CHICAGO, Ill., Jan. 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its fourth-quarter and full-year 2013 financial results on Friday, Jan. 31, 2014, before the market opens.

NORTH CHICAGO, Ill., Dec. 20, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 32^nd Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 15, 2014. Bill Chase, executive vice president and chief financial officer, will make a formal presentation on the company at 11 a.m. Central time.

NORTH CHICAGO, Ill., Dec. 10, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) released phase III results for the investigational three direct-acting-antiviral (3D) regimen plus ribavirin in patients with chronic, genotype 1 (GT1) hepatitis C virus (HCV) infection. In the 394-patient SAPPHIRE-II study, 96 percent of patients who previously failed pegylated interferon and ribavirin treatment, including approximately 49 percent of who were prior null responders, achieved sustained virologic response at 12 weeks (SVR₁₂) with the regimen. The majority of patients were GT1a, considered a difficult-to-treat subtype, and the SVR₁₂ rates of GT1a and GT1b were 96 percent and 97 percent, respectively. Virologic relapse or breakthrough was noted in 2 percent of patients receiving the 3D regimen plus ribavirin. In addition, the discontinuation rate due to adverse events was 1 percent.

NORTH CHICAGO, Ill., Nov. 26, 2013 /PRNewswire/ -- In advance of World AIDS Day on December 1, 2013, AbbVie (NYSE: ABBV) today announced the launch of See Us: Women Take a Stand on HIV, an international awareness campaign focused on helping to address the unique challenges faced by women living with HIV. The campaign is being launched in collaboration with an expert steering committee, which includes representation from women living with and affected by HIV, the medical community, the International Association of Providers in AIDS Care (IAPAC), and NAM/aidsmap, the HIV information charity.

NORTH CHICAGO, Ill., Nov. 18, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) released the first phase III results for the investigational three direct-acting-antiviral (3D) regimen plus ribavirin in patients chronically infected with genotype 1 (GT1) hepatitis C virus (HCV). In the 631-patient SAPPHIRE-I study, patients new to therapy receiving 12 weeks of AbbVie's 3D regimen achieved a sustained virologic response at 12 weeks post-treatment (SVR₁₂) of 96 percent. The majority of patients were GT1a, considered the more difficult-to-treat subtype, and the SVR₁₂ rates of GT1a and GT1b were 95 percent and 98 percent, respectively. The rate of virologic relapse or breakthrough was low, occurring in 1.7 percent of patients receiving the 3D regimen. In addition, discontinuation rates due to adverse events were low, and of an equal percentage (0.6 percent) in both active and placebo groups.

NORTH CHICAGO, Ill., Nov. 18, 2013 /PRNewswire/ -- AbbVie, one of the nation's largest biopharmaceutical companies, and the North Chicago public schools announce a $350,000 grant for math education.  The grant will enable educators to strengthen and reinforce the math curriculum for students (K-8) in the district and assist in the implementation of an engaging, common core aligned curriculum designed to increase both the educator and student understanding of and proficiency in mathematics.

NORTH CHICAGO, Ill., Nov. 14, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Jefferies 2013 Healthcare Conference on Thursday, Nov. 21, 2013. Scott Brun, M.D., vice president, pharmaceutical development, will take part in a question and answer session at 10:40 a.m. Greenwich Meantime (4:40 a.m. Central time).

NORTH CHICAGO, Ill, Nov. 7, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Credit Suisse 2013 Healthcare Conference on Thursday, Nov. 14, 2013. Bill Chase, executive vice president and chief financial officer, and Scott Brun, M.D., vice president, pharmaceutical development, will take part in a question and answer session at 9:30 a.m. Central time.